Medical Dermatology
News
Phase 3 study of novel pemphigus treatment is initiated
Results of a phase 2 study of the BTK inhibitor were positive.
Conference Coverage
Lower-dose rituximab may be enough in acquired TTP
SAN DIEGO – A lower dose of rituximab appears effective, but it still carries side effects.
Conference Coverage
Skin rashes often accompany drug-induced liver injury
SAN FRANCISCO – A survey of drug-induced liver and skin injuries finds they often co-occur and identifies some classes of drugs associated with...
Conference Coverage
Three drugs disappoint in SSc trials, but show some promise
CHICAGO – Recent randomized, placebo-controlled, phase 3 trials of tocilizumab, abatacept, and riociguat for the...
Feature
ACR CRISS: A way forward for scleroderma treatment trials?
From the Journals
Short-term lung function better predicts mortality risk in SSc
Surrogate measures of lung disease progression may help to determine the need for early intervention.
From the Journals
Study identifies potential biomarkers for an increased risk of SCARs-related mortality
Higher levels of elafin, IL-6, and TNF-alpha may be predictive of a greater risk of death in cancer patients with severe cutaneous adverse...
Conference Coverage
Fear of blindness hobbles hydroxychloroquine treatment of SLE
From the Journals
AEDs strongly linked to rare serious skin reactions
The highest-risk AEDs were zonisamide, rufinamide, clorazepate, lamotrigine, carbamazepine, and phenytoin.
Conference Coverage
Tofacitinib impresses in first trial for dermatomyositis
CHICAGO – Evidence of strong clinical efficacy noted.
Make the Diagnosis
A 77-year-old white male with a history of multiple nonmelanoma skin cancers as well as melanoma presented with an asymptomatic pink plaque on the vertex of the scalp.
A 77-year-old white male with a history of multiple nonmelanoma and melanoma skin cancers presented with an asymptomatic pink plaque on his scalp...